Literature DB >> 7981016

Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole.

A J van der Ven1, M A Mantel, T B Vree, P P Koopmans, J W van der Meer.   

Abstract

The formation and elimination of sulphamethoxazole hydroxylamine in relation to the pharmacokinetics of the parent compound and its N4-acetyl metabolite were investigated in six healthy subjects after a single oral dose of 800 mg sulphamethoxazole. The apparent half-lives of sulphamethoxazole and its metabolites were approximately 10 h, indicative of formation rate-limited metabolism. The mean residence time of the hydroxylamine metabolite was 5.5 +/- 1.5 h. The renal clearance of sulphamethoxazole hydroxylamine was 4.39 +/- 0.91 l h-1. The urinary recovery of sulphamethoxazole accounted for 16.5 +/- 5.5% of the dose, N4-acetyl-sulphamethoxazole for 46.2 +/- 6.6% and the hydroxylamine metabolite for 2.4 +/- 0.8%. The remaining 35% of the dose was unaccounted for. Acetylator phenotype was determined using sulphadimidine. The renal excretion of sulphamethoxazole hydroxylamine was 1.9 +/- 0.9% in slow acetylators (n = 3) and 2.8 +/- 0.3% in fast acetylators (n = 3); for N4-acetyl-sulphamethoxazole the values were 48 +/- 6% and 44 +/- 8%, respectively. Sulphamethoxazole is metabolized, although to a limited extent, to a hydroxylamine metabolite. This metabolite may be important for the pathogenesis of adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981016      PMCID: PMC1364861          DOI: 10.1111/j.1365-2125.1994.tb04339.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Authors:  J H Proost; D K Meijer
Journal:  Comput Biol Med       Date:  1992-05       Impact factor: 4.589

Review 2.  Adverse reactions to co-trimoxazole in HIV infection.

Authors:  A J van der Ven; P P Koopmans; T B Vree; J W van der Meer
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

3.  Systemic glutathione deficiency in symptom-free HIV-seropositive individuals.

Authors:  R Buhl; H A Jaffe; K J Holroyd; F B Wells; A Mastrangeli; C Saltini; A M Cantin; R G Crystal
Journal:  Lancet       Date:  1989-12-02       Impact factor: 79.321

4.  Clinical pharmacokinetics of sulfonamides and their metabolites: an encyclopedia.

Authors:  T B Vree; Y A Hekster
Journal:  Antibiot Chemother (1971)       Date:  1987

5.  Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides.

Authors:  M J Rieder; J Uetrecht; N H Shear; S P Spielberg
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

6.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

7.  Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.

Authors:  M J Rieder; N H Shear; A Kanee; B K Tang; S P Spielberg
Journal:  Clin Pharmacol Ther       Date:  1991-01       Impact factor: 6.875

8.  Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.

Authors:  T B Vree; W J O'Reilly; Y A Hekster; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

9.  Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity.

Authors:  N H Shear; S P Spielberg; D M Grant; B K Tang; W Kalow
Journal:  Ann Intern Med       Date:  1986-08       Impact factor: 25.391

10.  In vitro evaluation of a toxic metabolite of sulfadiazine.

Authors:  N H Shear; S P Spielberg
Journal:  Can J Physiol Pharmacol       Date:  1985-11       Impact factor: 2.273

View more
  8 in total

Review 1.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

2.  Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones.

Authors:  B Schnyder; D Mauri-Hellweg; M Zanni; F Bettens; W J Pichler
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.

Authors:  Payal Bhaiya; Sanjoy Roychowdhury; Piyush M Vyas; Mark A Doll; David W Hein; Craig K Svensson
Journal:  Toxicol Appl Pharmacol       Date:  2006-04-17       Impact factor: 4.219

4.  Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection.

Authors:  Yat Yee Wong; Eva G Rakasz; David J Gasper; Thomas C Friedrich; Lauren A Trepanier
Journal:  Toxicology       Date:  2016-08-23       Impact factor: 4.221

5.  Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole.

Authors:  A J van der Ven; T B Vree; E W van Ewijk-Beneken Kolmer; P P Koopmans; J W van der Meer
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

Review 6.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

7.  Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.

Authors:  E Zielińska; W Niewiarowski; J Bodalski; G Rebowski; J Skretkowicz; K Mianowska; M Sekulska
Journal:  Pharm World Sci       Date:  1998-06

8.  Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.

Authors:  David Pierce; Mary Corcoran; Patrick Martin; Karen Barrett; Susi Inglis; Peter Preston; Thomas N Thompson; Sandra K Willsie
Journal:  Drug Des Devel Ther       Date:  2014-05-14       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.